Cellular Biomedicine Group, Inc. is a holding company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. It specializes in immune cell therapy. The company was founded in 2009 and is headquartered in New York, NY.
Company profile
Ticker
CBMG
Exchange
Website
CEO
Tony Liu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EastBridge Investment Group Corp
SEC CIK
Corporate docs
IRS number
861032927
CBMG stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
3 Mar 21
EFFECT
Notice of effectiveness
26 Feb 21
EFFECT
Notice of effectiveness
26 Feb 21
EFFECT
Notice of effectiveness
26 Feb 21
EFFECT
Notice of effectiveness
26 Feb 21
25-NSE
Exchange delisting
19 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Feb 21
POS AM
Prospectus update (post-effective amendment)
19 Feb 21
POS AM
Prospectus update (post-effective amendment)
19 Feb 21
POS AM
Prospectus update (post-effective amendment)
19 Feb 21
Latest ownership filings
SC 13D/A
NOVARTIS PHARMA AG
24 Feb 21
SC 13D/A
Dangdai International Group Co. Ltd
22 Feb 21
SC 13D/A
Liu Tony
19 Feb 21
4
Chun Kwok Alan Au
19 Feb 21
4
Gang Jacky Ji
19 Feb 21
4
Terry Belmont
19 Feb 21
4
Hansheng Zhou
19 Feb 21
4
Edward T Schafer
19 Feb 21
4
Wen Tao Liu
19 Feb 21
4
Yihong Yao
19 Feb 21
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.03 mm | 26.03 mm | 26.03 mm | 26.03 mm | 26.03 mm | 26.03 mm |
Cash burn (monthly) | (no burn) | 2.56 mm | 5.90 mm | 4.94 mm | 4.45 mm | 3.56 mm |
Cash used (since last report) | n/a | 109.72 mm | 252.97 mm | 211.88 mm | 190.98 mm | 152.80 mm |
Cash remaining | n/a | -83.69 mm | -226.95 mm | -185.85 mm | -164.95 mm | -126.78 mm |
Runway (months of cash) | n/a | -32.7 | -38.5 | -37.6 | -37.1 | -35.6 |
Institutional ownership, Q1 2023
10.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 31.39 mm |
Total shares | 2.07 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sailing Capital Overseas Investments Fund | 1.71 mm | $25.95 mm |
TF Venture Capital Management | 358.97 k | $5.44 mm |
Liu Tony | 12.00 | $0.00 |